[go: up one dir, main page]

PL2925888T3 - Kompozycje i sposoby do stosowania w leczeniu nowotworów - Google Patents

Kompozycje i sposoby do stosowania w leczeniu nowotworów

Info

Publication number
PL2925888T3
PL2925888T3 PL13858495T PL13858495T PL2925888T3 PL 2925888 T3 PL2925888 T3 PL 2925888T3 PL 13858495 T PL13858495 T PL 13858495T PL 13858495 T PL13858495 T PL 13858495T PL 2925888 T3 PL2925888 T3 PL 2925888T3
Authority
PL
Poland
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Application number
PL13858495T
Other languages
English (en)
Inventor
Stuart Denham Shumway
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of PL2925888T3 publication Critical patent/PL2925888T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13858495T 2012-11-28 2013-11-22 Kompozycje i sposoby do stosowania w leczeniu nowotworów PL2925888T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730795P 2012-11-28 2012-11-28
PCT/US2013/071377 WO2014085216A1 (en) 2012-11-28 2013-11-22 Compositions and methods for treating cancer
EP13858495.8A EP2925888B1 (en) 2012-11-28 2013-11-22 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
PL2925888T3 true PL2925888T3 (pl) 2018-03-30

Family

ID=50828365

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13858495T PL2925888T3 (pl) 2012-11-28 2013-11-22 Kompozycje i sposoby do stosowania w leczeniu nowotworów

Country Status (23)

Country Link
US (1) US9655899B2 (pl)
EP (1) EP2925888B1 (pl)
JP (1) JP6290237B2 (pl)
KR (1) KR102161331B1 (pl)
AU (1) AU2013352568B2 (pl)
BR (1) BR112015012295A8 (pl)
CA (1) CA2892361A1 (pl)
CY (1) CY1119676T1 (pl)
DK (1) DK2925888T3 (pl)
ES (1) ES2651347T3 (pl)
HR (1) HRP20180002T1 (pl)
HU (1) HUE035662T2 (pl)
LT (1) LT2925888T (pl)
ME (1) ME02925B (pl)
MX (1) MX363243B (pl)
NO (1) NO2941224T3 (pl)
PL (1) PL2925888T3 (pl)
PT (1) PT2925888T (pl)
RS (1) RS56680B1 (pl)
RU (1) RU2660349C2 (pl)
SI (1) SI2925888T1 (pl)
SM (1) SMT201700595T1 (pl)
WO (1) WO2014085216A1 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US20180325902A1 (en) * 2015-11-06 2018-11-15 The Penn State Research Foundation Compositions and methods relating to cancer
US10280348B2 (en) * 2017-01-31 2019-05-07 Prc-Desoto International, Inc. Low density aerospace compositions and sealants
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
BR112022012286A2 (pt) * 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
WO2021127041A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MX2022012181A (es) * 2020-04-01 2023-01-30 Engine Biosciences Pte Ltd Metodos y composiciones para tratar cancer.
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
PT118269A (pt) 2022-10-20 2024-04-22 Univ Aveiro Pkmyt1 for use in regenerative medicine
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (393)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378110B (pl) 1972-05-19 1975-08-18 Bofors Ab
SE378109B (pl) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US6551784B2 (en) 1989-06-07 2003-04-22 Affymetrix Inc Method of comparing nucleic acid sequences
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
WO1991009844A1 (en) 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
EP0515681A4 (en) 1990-02-15 1993-12-29 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5451586A (en) 1990-06-01 1995-09-19 Pfizer Inc. 3-amino-2-aryl quinuclidines
US5422354A (en) 1990-07-23 1995-06-06 Pfizer Inc Quinuclidine derivatives
ES2071334T3 (es) 1990-09-28 1995-06-16 Pfizer Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
GB9023116D0 (en) 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
DK0498069T3 (da) 1990-12-21 1995-12-04 Fujisawa Pharmaceutical Co Ny anvendelse af peptidderivat
FI933167A7 (fi) 1991-01-10 1993-07-09 Pfizer N-alkyylikinuklidiniumsuolat aineen P antagonisteina
EP0499313B1 (en) 1991-02-11 1997-06-11 MERCK SHARP & DOHME LTD. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
DE69200921T2 (de) 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
PL169993B1 (pl) 1991-03-26 1996-09-30 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL PL
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
US5292726A (en) 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
RU2092486C1 (ru) 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины
DE122006000066I2 (de) 1991-05-31 2007-12-06 Pfizer Chinuclidinderivate
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
BR9206161A (pt) 1991-06-20 1995-10-31 Pfizer Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
TW202432B (pl) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
DE69208088T2 (de) 1991-07-05 1996-11-14 Merck Sharp & Dohme Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
EP0536817A1 (en) 1991-07-05 1993-04-14 MERCK SHARP & DOHME LTD. Azabicyclic compounds as tachykinin antagonists
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06509090A (ja) 1991-07-10 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む組成物、及び治療におけるそれらの使用
WO1993001159A1 (en) 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
WO1993004040A1 (en) 1991-08-20 1993-03-04 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
PT533280E (pt) 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
CZ59394A3 (en) 1991-09-26 1994-11-16 Pfizer Condensed tricyclic heterocycles containing nitrogen as antagonists of p substance receptor, process of their preparation, intermediates, pharmaceutical preparations in which they are comprised and use
WO1993009116A1 (fr) 1991-11-07 1993-05-13 Yoshitomi Pharmaceutical Industries, Ltd. Compose a base de quinuclidine et utilisation dudit compose en medecine
DK0613458T3 (da) 1991-11-12 1998-02-09 Pfizer Acykliske ethylendiaminderivater som substans P receptorantagonister
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
GB9201179D0 (en) 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
JP2656702B2 (ja) 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin-Elmer Corp., Foster City, Calif. Proben zusammensetzung und verfahren
FR2689888B1 (fr) 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
CA2133077A1 (en) 1992-04-15 1993-10-28 Raymond Baker Azacyclic compounds
GB2266529A (en) 1992-05-01 1993-11-03 Merck Sharp & Dohme Tetrahydroisoquinoline derivatives
CA2134964C (en) 1992-05-18 1997-12-30 Manoj C. Desai Bridged aza-bicyclic derivatives as substance p antagonists
GB9211193D0 (en) 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
US5637699A (en) 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2099233A1 (en) 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
GB2268931A (en) 1992-07-22 1994-01-26 Merck Sharp & Dohme Azabicyclic tachykinin-receptor antagonists
AU675447B2 (en) 1992-07-28 1997-02-06 Merck Sharp & Dohme Limited Carboxamidomethyl piperidine and analogues
GB2269170A (en) 1992-07-29 1994-02-02 Merck Sharp & Dohme Azatricyclic tachykinin antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
CA2141051A1 (en) 1992-08-04 1994-02-17 Terry J. Rosen Substituted nitrogen-containing heterocycles
GB9216911D0 (en) 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
DK0655055T3 (da) 1992-08-13 2001-01-02 Warner Lambert Co Tachykininantagonister
EP1114823A3 (en) 1992-08-19 2001-07-18 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
NO179904C (no) 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
AU4973693A (en) 1992-09-10 1994-03-29 Merck Sharp & Dohme Limited Alcohols and ethers with aromatic substituents as tachykinin-antagonists
GB9220286D0 (en) 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
GB9222262D0 (en) 1992-10-23 1992-12-09 Merck Sharp & Dohme Therapeutic agents
GB9222486D0 (en) 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
WO1994010165A1 (en) 1992-10-28 1994-05-11 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5554627A (en) 1992-10-30 1996-09-10 Merck, Sharp & Dohme Ltd. Tachykinin antagonists
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
ES2096312T3 (es) 1992-11-12 1997-03-01 Pfizer Derivado de quinuclidina como antagonista de la sustancia p.
US5261188A (en) 1992-11-23 1993-11-16 The Standard Products Company Belt weatherstrip with bulb
PT675886E (pt) 1992-12-10 2000-12-29 Pfizer Heterociclos nao aromaticos com substituintes aminometileno e sua utilizacao como antagonistas da substancia p
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
JPH08504435A (ja) 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
GB9226581D0 (en) 1992-12-21 1993-02-17 Merck Sharp & Dohme Therapeutic agents
CA2111902A1 (en) 1992-12-21 1994-06-22 Jack Beuford Campbell Antitumor compositions and methods of treatment
GB9300051D0 (en) 1993-01-04 1993-03-03 Merck Sharp & Dohme Therapeutic agents
CA2152792C (en) 1993-01-15 2000-02-15 Stephen R. Bertenshaw Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
EP0610793A1 (en) 1993-02-08 1994-08-17 Takeda Chemical Industries, Ltd. Tetracyclic morpholine derivatives and their use or analgesics
JPH08506823A (ja) 1993-02-18 1996-07-23 メルク シヤープ エンド ドーム リミテツド アザ環式化合物、該化合物を含む組成物及びタキキニン拮抗剤としての該化合物の使用
AU6140694A (en) 1993-02-22 1994-09-14 Merck Sharp & Dohme Limited Aromatic compounds, compositions containing them and their use in therapy
WO1994019357A1 (en) 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5688806A (en) 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
DE4311230C2 (de) 1993-04-02 1996-12-19 Mannesmann Ag Nicht-spurgebundenes Fahrzeug mit Elektromotor
US5496833A (en) 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
EP0696280B1 (en) 1993-05-06 1997-09-24 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
WO1994026723A2 (en) 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
AU680020B2 (en) 1993-06-07 1997-07-17 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
EP0634402A1 (en) 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
ES2121213T3 (es) 1993-07-15 1998-11-16 Pfizer Benciloxiquinuclidinas como antagonistas de la sustancia p.
GB9315808D0 (en) 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
TW365603B (en) 1993-07-30 1999-08-01 Rhone Poulenc Rorer Sa Novel perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them
GB9317987D0 (en) 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
DE69433744T2 (de) 1993-09-17 2004-10-14 Pfizer Inc. 3-amino-5-carboxy-substituierte piperidine und 3-amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten
EP0719266A1 (en) 1993-09-17 1996-07-03 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
WO1995008542A1 (en) 1993-09-22 1995-03-30 Kyowa Hakko Kogyo Co., Ltd. Farnesyltransferase inhibitor
IS4208A (is) 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
ES2164717T3 (es) 1993-10-15 2002-03-01 Schering Corp Compuestos triciclicos de sulfonamida utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
ATE210652T1 (de) 1993-10-15 2001-12-15 Schering Corp Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
KR100378615B1 (ko) 1993-10-25 2003-10-10 파크데이비스앤드캄파니 단백질:파르네실트랜스퍼라제의치환된테트라및펜타펩티드억제제
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
AU7947594A (en) 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
WO1995012572A1 (en) 1993-11-04 1995-05-11 Abbott Laboratories Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase
KR100362338B1 (ko) 1993-11-05 2003-04-08 워너-램버트 캄파니 단백질:파르네실트랜스퍼라아제의치환디-및트리펩티드억제제
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
IT1271462B (it) 1993-12-03 1997-05-28 Menarini Farma Ind Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
JPH09506898A (ja) 1993-12-21 1997-07-08 イーライ・リリー・アンド・カンパニー 非ペプチドタキキニン受容体アンタゴニスト
KR100286412B1 (ko) 1993-12-29 2001-04-16 더블유. 지. 콜 치환된 모르폴린 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE69416869T2 (de) 1993-12-29 1999-07-01 Pfizer Inc., New York, N.Y. Diazabicyclische neurokinin antagonisten
JPH09507500A (ja) 1994-01-13 1997-07-29 メルク シヤープ エンド ドーム リミテツド ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬
WO1995020575A1 (en) 1994-01-28 1995-08-03 Merck Sharp & Dohme Limited Aralkylamino substituted azacyclic therapeutic agents
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
GB9402688D0 (en) 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents
US5610165A (en) 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
WO1995024612A1 (de) 1994-03-07 1995-09-14 International Business Machines Corporation Verfahren und vorrichtung zur schnellen interpolation von zwischenwerten aus periodischen phasenverschobenen signalen und zur erkennung von defekten in einem drehkörper
FI963597L (fi) 1994-03-15 1996-11-14 Eisai Co Ltd Isoprenyylitransferaasi-inhibiittoreita
FR2718136B1 (fr) 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
HUT72440A (en) 1994-03-31 1996-04-29 Bristol Myers Squibb Co Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5747491A (en) 1994-05-05 1998-05-05 Merck Sharp & Dohme Ltd. Morpholine derivatives and their use as antagonists of tachikinins
JPH09512806A (ja) 1994-05-07 1997-12-22 ベーリンガー インゲルハイム コマンディトゲゼルシャフト 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物（ｉｉ）
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5563255A (en) 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
JPH10501228A (ja) 1994-06-06 1998-02-03 ワーナー−ランバート・コンパニー タキキニン（ｎｋ▲下１▼）受容体アンタゴニスト
EP0686629A3 (en) 1994-06-10 1999-02-10 Eli Lilly And Company Cyclohexyl tachykinine receptor antagonists
CN1150419A (zh) 1994-06-10 1997-05-21 罗纳-布朗克罗莱尔股份有限公司 新的法呢基转移酶抑制剂、其制法及其药物组合物
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CZ288434B6 (en) 1994-07-12 2001-06-13 Lilly Co Eli Dihydrochloride trihydrate of (R)-3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)acetylamino]-2-[N-/2-(4-piperid-1-yl)piperid-1-yl)acetyl/-amino]propane, pharmaceutical preparation in which it is comprised and use thereof
CA2154116A1 (en) 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
GB9415997D0 (en) 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB9415996D0 (en) 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
WO1996005529A1 (en) 1994-08-09 1996-02-22 Micron Optics, Inc. Temperature compensated fiber fabry-perot filters
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
WO1996005168A1 (en) 1994-08-11 1996-02-22 Banyu Pharmaceutical Co., Ltd. Substituted amide derivative
WO1996005169A1 (en) 1994-08-12 1996-02-22 Banyu Pharmaceutical Co., Ltd. N,n-disubstituted amic acid derivative
WO1996005181A1 (en) 1994-08-15 1996-02-22 Merck Sharp & Dohme Limited Morpholine derivatives and their use as therapeutic agents
DE4429506B4 (de) 1994-08-19 2007-09-13 Degussa Gmbh Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe
DE4429653C2 (de) 1994-08-20 1997-04-03 Anton Dr More Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl
WO1996006094A1 (en) 1994-08-25 1996-02-29 Merrell Pharmaceuticals Inc. Novel substituted piperidines useful for the treatment of allergic diseases
ATE158568T1 (de) 1994-08-29 1997-10-15 Akzo Nobel Nv Verfahren zur herstellung von quaternären diestern
GB9417956D0 (en) 1994-09-02 1994-10-26 Merck Sharp & Dohme Therapeutic agents
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
US5457107A (en) 1994-09-16 1995-10-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
CA2198382A1 (en) 1994-09-30 1996-04-11 Novartis Ag 1-acyl-4-aliphatylaminopiperidine compounds
TW397825B (en) 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725986B1 (fr) 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
GB9421709D0 (en) 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
WO1996016443A1 (en) 1994-11-22 1996-05-30 Philips Electronics N.V. Semiconductor device with a carrier body on which a substrate with a semiconductor element is fastened by means of a glue layer and on which a pattern of conductor tracks is fastened
EP0714891A1 (en) 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists
FR2727411B1 (fr) 1994-11-30 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2204144A1 (en) 1994-12-09 1996-06-13 Francis J. Tinney Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
IL116323A0 (en) 1994-12-13 1996-03-31 Sandoz Ag Tachykinin antagonists their preparation and pharmaceutical compositions containing them
GB9426103D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
WO1996021701A2 (en) 1995-01-09 1996-07-18 Magla International Ltd. Wear resistant image printing on latex surfaces
AU4915796A (en) 1995-01-12 1996-07-31 University Of Pittsburgh Inhibitors of prenyl transferases
ATE279406T1 (de) 1995-01-12 2004-10-15 Glaxo Group Ltd Piperidinderivate mit tachykinin-antagonistischer wirkung
FR2729390A1 (fr) 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2729951B1 (fr) 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2730492B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
GB9505492D0 (en) 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9505491D0 (en) 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
US5554641A (en) 1995-03-20 1996-09-10 Horwell; David C. Nonpeptides as tachykinin antagonists
GB9505692D0 (en) 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
TW394773B (en) 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
CA2217351C (en) 1995-04-07 2003-03-18 Schering Corporation Carbonyl-piperazinyl and piperidinyl compounds which inhibit farnesyl protein transferase
AU700693B2 (en) 1995-04-13 1999-01-14 Aventis Pharmaceuticals Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
IL118101A0 (en) 1995-05-03 1996-09-12 Abbott Lab Inhibitors of farnesyltransferase
HUP9900822A3 (en) 1995-05-25 1999-11-29 Fujisawa Pharmaceutical Co Piperazine derivatives, process for producing them, pharmaceutical compositions containing them and method for treating tachykinin-mediated diseases
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
WO1997000252A1 (en) 1995-06-16 1997-01-03 Warner-Lambert Company Tricyclic inhibitors of protein farnesyltransferase
GB9513118D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513121D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
US6180647B1 (en) 1995-07-07 2001-01-30 Pfizer Inc. Substituted benzolactam compounds as substance P antagonists
FR2736641B1 (fr) 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
AT402617B (de) 1995-07-11 1997-07-25 Datacon Schweitzer & Zeindl Gm Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen
FR2736638B1 (fr) 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
CH690163A5 (fr) 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
TW340842B (en) 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
JP2002534955A (ja) 1995-10-18 2002-10-15 メルク エンド カンパニー インコーポレーテッド シクロペンチルタキキニン受容体アンタゴニスト
CA2235986C (en) 1995-11-06 2006-09-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
DE19541283A1 (de) 1995-11-06 1997-05-07 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9523244D0 (en) 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US6288237B1 (en) 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
EP0862435A4 (en) 1995-11-22 1999-02-03 Merck & Co Inc Inhibitors of farnesyl-protein transferase
US6060469A (en) 1995-11-23 2000-05-09 Merck Sharp & Dohme Ltd. Spiro-piperidine derivatives and their use as tachykinin antagonists
GB9524157D0 (en) 1995-11-25 1996-01-24 Pfizer Ltd Therapeutic agents
HU224225B1 (hu) 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
EE03484B1 (et) 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
GB9525296D0 (en) 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
EP1380581A1 (en) 1995-12-22 2004-01-14 Schering Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1997026246A1 (en) 1996-01-16 1997-07-24 Warner-Lambert Company Substituted histidine inhibitors of protein farnesyltransferase
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US5744349A (en) * 1996-03-05 1998-04-28 Washington University DNA sequences encoding human Myt1 kinase
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
EP0938494A1 (en) 1996-05-22 1999-09-01 Warner-Lambert Company Inhibitors of protein farnesyl transferase
EP0918771A4 (en) 1996-07-15 2001-02-07 Bristol Myers Squibb Co THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6020194A (en) * 1996-10-04 2000-02-01 California Institute Of Technology DNA encoding a Myt1 polypeptide
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2276150A1 (en) 1996-12-30 1998-07-09 Steven D. Young Inhibitors of farnesyl-protein transferase
JP2002511054A (ja) 1996-12-30 2002-04-09 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白トランスフェラーゼ阻害薬
ID29970A (id) 1998-11-23 2001-10-25 Novartis Ag Metode untuk mengobati penyakit neovaskuler okuler
CA2361553A1 (en) 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
US6077674A (en) 1999-10-27 2000-06-20 Agilent Technologies Inc. Method of producing oligonucleotide arrays with features of high purity
JP2003528076A (ja) 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
GB0025173D0 (en) 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
JP3880051B2 (ja) 2000-11-02 2007-02-14 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害剤としてのスルファミド
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
WO2002083140A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
ATE400274T1 (de) 2001-04-10 2008-07-15 Merck & Co Inc Hemmstoffe der akt aktivität
WO2002083064A2 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
JP3711131B2 (ja) 2001-08-21 2005-10-26 メルク シャープ エンド ドーム リミテッド 新規のシクロヘキシルスルホン
AU2002332122A1 (en) 2001-10-15 2003-04-28 The Medstar Research Institute Modulation of akt-dependent response to prevent restenosis
WO2003035048A2 (en) 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
US7060705B2 (en) 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
EP1481077B1 (en) 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
CA2467916A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
CA2478068C (en) 2002-03-08 2011-02-08 Merck & Co., Inc. Dihydropyrazole compounds useful for treating or preventing cancer
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003084473A2 (en) 2002-04-08 2003-10-16 Merck & Co., Inc. Method of treating cancer
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
ATE435219T1 (de) 2002-05-01 2009-07-15 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4377323B2 (ja) 2002-06-14 2009-12-02 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP4463679B2 (ja) 2002-06-14 2010-05-19 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223040D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
EP1556052A4 (en) 2002-10-18 2006-11-02 Merck & Co Inc MITOTIC KINESINE HEMMER
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
AU2003295843A1 (en) 2002-12-06 2004-06-30 Pharmacia Corporation Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
EP1581497A4 (en) 2002-12-20 2009-03-18 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
WO2004058700A2 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
CN100422158C (zh) 2003-04-24 2008-10-01 麦克公司 Akt活性抑制剂
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1631548B1 (en) 2003-04-24 2009-10-28 Merck & Co., Inc. Inhibitors of akt activity
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
MXPA05012323A (es) 2003-05-16 2006-01-30 Merck Sharp & Dohme Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
JP2007501863A (ja) 2003-06-12 2007-02-01 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
CA2686618A1 (en) 2003-07-17 2005-01-17 At&T Corp. Method and apparatus for windowing in entropy encoding
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
KR100536215B1 (ko) 2003-08-05 2005-12-12 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
CA2533435A1 (en) 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1835756A (zh) 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
CA2534729A1 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
US20060234984A1 (en) 2003-08-15 2006-10-19 Coleman Paul J Mitotic kinesin inhibitors
AR045342A1 (es) 2003-08-15 2005-10-26 Merck & Co Inc Inhibidores de quinesina mitotica
CA2539042A1 (en) 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
US7294640B2 (en) 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2561311A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
WO2006091395A2 (en) 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
EP1871376A4 (en) 2005-04-12 2010-04-28 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
PL1898903T3 (pl) 2005-06-10 2013-08-30 Merck Sharp & Dohme Inhibitory aktywności Akt
EP1963531B1 (en) 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
MX2009013728A (es) 2007-06-15 2010-01-25 Banyu Pharma Co Ltd Derivados de bicicloanilina.
EP2303885B1 (en) * 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
US8703779B2 (en) * 2009-09-15 2014-04-22 Merck Sharp & Dohme Corp. Preparation of crystalline forms of dihydropyrazolopyrimidinone
EP2640386B1 (en) * 2010-11-16 2017-01-18 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
WO2013039854A1 (en) * 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
EP2925888B1 (en) 2017-10-25
KR20150088257A (ko) 2015-07-31
WO2014085216A1 (en) 2014-06-05
HK1209798A1 (en) 2016-04-08
JP6290237B2 (ja) 2018-03-07
ES2651347T3 (es) 2018-01-25
NO2941224T3 (pl) 2018-07-28
US20160008361A1 (en) 2016-01-14
MX2015006729A (es) 2015-08-14
RS56680B1 (sr) 2018-03-30
KR102161331B1 (ko) 2020-09-29
RU2660349C2 (ru) 2018-07-05
LT2925888T (lt) 2018-01-10
BR112015012295A2 (pt) 2017-07-11
EP2925888A4 (en) 2016-05-11
CA2892361A1 (en) 2014-06-05
MX363243B (es) 2019-03-14
DK2925888T3 (en) 2017-12-18
AU2013352568A1 (en) 2015-04-30
AU2013352568B2 (en) 2019-09-19
EP2925888A1 (en) 2015-10-07
HUE035662T2 (en) 2018-05-28
PT2925888T (pt) 2017-12-13
RU2015125575A (ru) 2017-01-10
SMT201700595T1 (it) 2018-03-08
SI2925888T1 (en) 2018-02-28
ME02925B (me) 2018-04-20
US9655899B2 (en) 2017-05-23
HRP20180002T1 (hr) 2018-02-09
BR112015012295A8 (pt) 2023-03-14
CY1119676T1 (el) 2018-04-04
JP2016500110A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
PT2925888T (pt) Composições e métodos para tratamento do cancro
IL227429A0 (en) The components and methods of cancer treatment
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
IL245281A0 (en) Methods and preparations for the treatment of cancer
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
IL237791A0 (en) A method for treating cancer
EP2734207A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
SG10201610251PA (en) Compositions and methods for cancer immunotherapy
DK3292875T3 (en) Compositions and methods for treating diseases
SG11201503893RA (en) Method of treating cancer
IL238177A0 (en) Methods and preparations for the treatment of cancer
SG10201500124VA (en) Methods and Compositions for Treating Cancer
IL234829A0 (en) Methods and preparations for treating inflammation
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
EP3004395A4 (en) Compositions and methods for treating cancer
IL229231A0 (en) Preparations and methods for the treatment of cancer
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2717865A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BRAIN CANCER
PT2915800T (pt) Compostos derivados de ingenol que podem ser utilizados para tratamento do cancro
EP2984185A4 (en) Methods and compositions for treating cancer
EP2537031A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2887967A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATOCELLULAR CANCER
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2014160368A9 (en) Compositions and methods for treating cancer